NCT01575548 2026-03-18
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT01684397 2026-02-27
Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer
Roswell Park Cancer Institute
Phase 1/2 Active not recruiting
NCT02184416 2026-02-27
ADONIS
Pfizer
Completed
NCT06726421 2026-01-15
STROKER
Sun Yat-sen University
Phase 3 Recruiting
NCT03260894 2025-07-29
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT07087158 2025-07-28
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Phase 2 Not yet recruiting
NCT03592472 2025-04-13
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)
Xynomic Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed